SAN JOSE, Calif., Dec. 2 Starch Medical Inc, a San Jose,CA-based medical device manufacturer, announces the CE approval of itsPerClot(TM) Polysaccharide Hemostatic System (PHS) and the StarFoam(TM)Absorbable Polysaccharide Hemostat. Introduction of PerClot(TM) PHS willcommence this month in the European Union and other select internationalmarkets. The StarFoam(TM) Absorbable Polysaccharide Hemostat will launchduring the 2nd quarter, 2009.
PerClot(TM) PHS is an absorbable, surgical hemostat composed of AbsorbableModified Polymers (AMP(TM)). AMP(TM) technology incorporates sophisticated,plant-based polymer modification processes that yield biocompatible,polysaccharide particles. There is no thrombin, collagen, or other human oranimal components in AMP(TM) particles. A family of customized, single-useapplication instruments will enhance the delivery of AMP(TM) to the wound sitefor the control of capillary, venous and arterial bleeding in both open andminimally invasive surgical procedures.
The StarFoam(TM) Absorbable Polysaccharide Hemostat, also developed withAMP(TM) technology, is produced in a hemostatic foam (wafer) configuration.Application of StarFoam(TM) will feature a simple "press and release"technique.
David Lang, President of SMI, commented, "The clinical introduction ofPerClot(TM) PHS and its proprietary, integrated AMP(TM) technology representsthe next generation of polysaccharide hemostatic agents. The StarFoam(TM)product line will offer surgeons a choice of hemostatic formats for a range ofsurgical wounds. Compared to current polysaccharide based hemostats,PerClot(TM) PHS and StarFoam(TM) demonstrate superior hydrophilic action andenhanced adhesive strength. These performance features, coupled with customdelivery systems, have been favorably received in a diverse range of surgicalapplications in Europe, Asia and Latin America."
SMI is a privately-held medical device company engaged in the design,manufacture, marketing and licensing of breakthrough, hemostatic solutions.Starch Medical's proprietary, patent-pending technology platform (AMP(TM)),including powders, foams and films, will focus on the worldwide, multi-billiondollar biomaterial, hemostasis, and wound care marketplace. For additionalinformation, distribution inquiries, and licensing options, visithttp://www.starchmedical.com.
SOURCE Starch Medical Inc